Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis

Authors

Rebecca Craig-Shapiro, Washington University School of Medicine in St. Louis
Max Kuhn, Pfizer
Chengjie Xiong, Washington University School of Medicine in St. Louis
Eve H. Pickering, Pfizer
Jingxia Liu, Washington University School of Medicine in St. Louis
Thomas P. Misko, Pfizer
Richard J. Perrin, Washington University School of Medicine in St. Louis
Kelly R. Bales, PfizerFollow
Holly Soares, Pfizer
Anne M. Fagan, Washington University School of Medicine in St. Louis
David H. Holtzman, Washington University School of Medicine in St. Louis

Areas of Expertise

Richard J. Perrin, 6500 Medical Disciplines; David H. Holtzman, 2890, Neurodegeneration

Journal

PLoS One

Volume

6

Issue

4

Document Type

Open Access Publication

Pages

e18850

Publication Date

2011

Recommended Citation

Craig-Shapiro, Rebecca; Kuhn, Max; Xiong, Chengjie; Pickering, Eve H.; Liu, Jingxia; Misko, Thomas P.; Perrin, Richard J.; Bales, Kelly R.; Soares, Holly; Fagan, Anne M.; and Holtzman, David H., "Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis". PLoS One, e18850. 2011. Paper 100.
https://digitalcommons.wustl.edu/icts_facpubs/100